AU596652B2 - New immunomodulators obtained semisynthetically from a bacterial polysaccharide isolated from a non-encapsulated mutant strain of klebsiella pneumoniae - Google Patents
New immunomodulators obtained semisynthetically from a bacterial polysaccharide isolated from a non-encapsulated mutant strain of klebsiella pneumoniae Download PDFInfo
- Publication number
- AU596652B2 AU596652B2 AU71415/87A AU7141587A AU596652B2 AU 596652 B2 AU596652 B2 AU 596652B2 AU 71415/87 A AU71415/87 A AU 71415/87A AU 7141587 A AU7141587 A AU 7141587A AU 596652 B2 AU596652 B2 AU 596652B2
- Authority
- AU
- Australia
- Prior art keywords
- derivative
- radical
- acid
- radicals
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 21
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 18
- 241000588747 Klebsiella pneumoniae Species 0.000 title description 4
- 230000001580 bacterial effect Effects 0.000 title description 4
- 239000002955 immunomodulating agent Substances 0.000 title description 3
- 229940121354 immunomodulator Drugs 0.000 title description 3
- 239000002253 acid Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001412 amines Chemical class 0.000 claims abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000001408 amides Chemical group 0.000 claims abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- -1 tertiary amino radicals Chemical class 0.000 claims description 17
- 150000003254 radicals Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical class C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000243 solution Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000008878 coupling Effects 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229960003082 galactose Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 150000002386 heptoses Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000013542 high molecular weight contaminant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003783 hymenoptera venom Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8606765A FR2598434B1 (fr) | 1986-05-12 | 1986-05-12 | Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae |
| FR8606765 | 1986-05-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7141587A AU7141587A (en) | 1987-11-19 |
| AU596652B2 true AU596652B2 (en) | 1990-05-10 |
Family
ID=9335114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU71415/87A Ceased AU596652B2 (en) | 1986-05-12 | 1987-04-10 | New immunomodulators obtained semisynthetically from a bacterial polysaccharide isolated from a non-encapsulated mutant strain of klebsiella pneumoniae |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4933440A (forum.php) |
| EP (1) | EP0246149B1 (forum.php) |
| JP (1) | JP2662951B2 (forum.php) |
| AT (1) | ATE84075T1 (forum.php) |
| AU (1) | AU596652B2 (forum.php) |
| CA (1) | CA1268900A (forum.php) |
| DE (1) | DE3783268T2 (forum.php) |
| ES (1) | ES2052590T3 (forum.php) |
| FR (1) | FR2598434B1 (forum.php) |
| GR (1) | GR3007433T3 (forum.php) |
| ZA (1) | ZA872782B (forum.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2614306B1 (fr) * | 1987-04-22 | 1989-07-28 | Pf Medicament | Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant. |
| DE3812181A1 (de) * | 1988-04-13 | 1989-10-26 | Werner E G Prof Dr Mueller | Arzneimittel, enthaltend natuerliche und/oder chemisch modifizierte mono- oder polysaccharide und deren verwendung |
| FR2644059B1 (fr) * | 1989-03-08 | 1994-03-04 | Fabre Medicament Pierre | Compositions aerosols destinees a l'imagerie, au diagnostic et a la therapie ciblee de foyers inflammatoires et tumoraux |
| FR2655267B1 (fr) * | 1989-12-04 | 1992-04-03 | Roussel Uclaf | Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant. |
| FR2659351B1 (fr) * | 1990-03-08 | 1994-12-02 | Pf Medicament | Compose polysaccharidique delipide, procede de preparation, compositions en comprenant. |
| EP0702697B2 (en) † | 1993-04-15 | 2003-08-20 | Akzo Nobel N.V. | Method of making amide modified carboxyl-containing polysaccharide and fatty amide-modified polysaccharide so obtainable |
| US6444210B1 (en) | 1996-07-03 | 2002-09-03 | Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty′s Canadian Goverment | Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity |
| ITTS20010017A1 (it) * | 2001-07-17 | 2003-01-17 | Ct Ricerche Polytech Soc Coop | Esteri polisaccaridici di acido retinoico. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089266A1 (fr) * | 1982-03-09 | 1983-09-21 | Pierre Fabre S.A. | Procédé de préparation de protéoglycanes immunostimulants inducteurs d'interféron, protéoglycanes obtenus et médicament les contenant |
| EP0115988A1 (fr) * | 1983-01-28 | 1984-08-15 | Roussel-Uclaf | Nouveau procédé de préparation d'acylglycoprotéines immunostimulantes extraites de Klebsiella pneumoniae, compositions pharmaceutiques antiallerqiques |
| AU5118085A (en) * | 1984-12-12 | 1986-06-19 | Hoechst A.G. | Extracellular polysaccharide |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL122086B1 (en) * | 1979-04-09 | 1982-06-30 | Politechnika Gdanska | Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh |
| US4593091A (en) * | 1981-08-04 | 1986-06-03 | Fidia, S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
| US4716223A (en) * | 1981-08-04 | 1987-12-29 | Fidia, S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
| US4476119A (en) * | 1981-08-04 | 1984-10-09 | Fidia S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
| IT1199116B (it) * | 1984-07-03 | 1988-12-30 | Fidia Farmaceutici | Derivati di gangliosidi |
| FR2570081B1 (fr) * | 1984-09-10 | 1987-01-09 | Pf Medicament | Polysaccharides membranaires utiles notamment comme medicament et procede pour leur preparation |
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4755381A (en) * | 1986-03-27 | 1988-07-05 | Swiss Serum And Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
-
1986
- 1986-05-12 FR FR8606765A patent/FR2598434B1/fr not_active Expired
-
1987
- 1987-04-08 CA CA000534169A patent/CA1268900A/fr not_active Expired - Fee Related
- 1987-04-10 AU AU71415/87A patent/AU596652B2/en not_active Ceased
- 1987-04-21 ZA ZA872782A patent/ZA872782B/xx unknown
- 1987-05-11 AT AT87401057T patent/ATE84075T1/de not_active IP Right Cessation
- 1987-05-11 EP EP87401057A patent/EP0246149B1/fr not_active Expired - Lifetime
- 1987-05-11 DE DE8787401057T patent/DE3783268T2/de not_active Expired - Fee Related
- 1987-05-11 ES ES87401057T patent/ES2052590T3/es not_active Expired - Lifetime
- 1987-05-12 JP JP62115719A patent/JP2662951B2/ja not_active Expired - Lifetime
- 1987-05-12 US US07/050,248 patent/US4933440A/en not_active Expired - Fee Related
-
1993
- 1993-03-23 GR GR930400620T patent/GR3007433T3/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089266A1 (fr) * | 1982-03-09 | 1983-09-21 | Pierre Fabre S.A. | Procédé de préparation de protéoglycanes immunostimulants inducteurs d'interféron, protéoglycanes obtenus et médicament les contenant |
| EP0115988A1 (fr) * | 1983-01-28 | 1984-08-15 | Roussel-Uclaf | Nouveau procédé de préparation d'acylglycoprotéines immunostimulantes extraites de Klebsiella pneumoniae, compositions pharmaceutiques antiallerqiques |
| AU5118085A (en) * | 1984-12-12 | 1986-06-19 | Hoechst A.G. | Extracellular polysaccharide |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7141587A (en) | 1987-11-19 |
| CA1268900A (fr) | 1990-05-08 |
| DE3783268D1 (de) | 1993-02-11 |
| JP2662951B2 (ja) | 1997-10-15 |
| DE3783268T2 (de) | 1993-05-19 |
| US4933440A (en) | 1990-06-12 |
| ZA872782B (en) | 1987-10-05 |
| ATE84075T1 (de) | 1993-01-15 |
| FR2598434B1 (fr) | 1988-09-16 |
| EP0246149A3 (en) | 1988-10-12 |
| EP0246149A2 (fr) | 1987-11-19 |
| JPS62273201A (ja) | 1987-11-27 |
| FR2598434A1 (fr) | 1987-11-13 |
| ES2052590T3 (es) | 1994-07-16 |
| GR3007433T3 (forum.php) | 1993-07-30 |
| EP0246149B1 (fr) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1181691A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
| Takakura et al. | Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran I: Synthesis and characterization | |
| AU596652B2 (en) | New immunomodulators obtained semisynthetically from a bacterial polysaccharide isolated from a non-encapsulated mutant strain of klebsiella pneumoniae | |
| DE2450355A1 (de) | Aus n-acyl-muraminsaeurederivaten gebildete adjuvanzien und diese enthaltende impfstoffe | |
| AU7580787A (en) | Lipopolysaccharides of reduced toxicity and the production thereof | |
| CA2210139A1 (en) | Immunogenic conjugate molecules | |
| US4372883A (en) | Process for the production of vaccine | |
| US4461761A (en) | Oligomers of compounds of the muramyl-peptide type and medicaments containing them | |
| US3888837A (en) | Tuberculin active proteins and peptides from the cells of tubercle bacilli | |
| US4412946A (en) | Immunostimulating glycoproteins | |
| CA1338948C (en) | Composition for macrophage activation | |
| EP0201332A2 (en) | A substance having an anti-infective activity | |
| US5416070A (en) | Composition for macrophage activation | |
| GB2053232A (en) | Dipeptides their preparation and the medicaments in which they are present | |
| JPH0587519B2 (forum.php) | ||
| RU2073016C1 (ru) | Способ получения низкомолекулярного водорастворимого хитозана | |
| US4014992A (en) | Acetylated watersoluble extracts of corynebacteria, process for obtaining them and their use | |
| WO2004003215A1 (en) | Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides | |
| US4110434A (en) | Novel immunological adjuvants, process for their production and compositions containing them | |
| AU644604B2 (en) | Extracellular exopolymer, process for its preparation and pharmaceutical compositions containing the said exopolymer | |
| HU185315B (en) | Siliconpolymer compositions for treating textile materials | |
| AU616403B2 (en) | Novel derivative of d.25, process for its preparation, its use as an immunostimulant, and pharmaceutical compositions containing the derivative | |
| US4157278A (en) | Immunostimulatory agents | |
| US5142027A (en) | Cationized carriers for immunogen production | |
| Jollès | Hydrosoluble immunostimulants of bacterial and synthetic origins |